"rationale","instanceType","versionIdentifier","uuid:ID","id"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion","2","5586cd3f-d5a0-43d1-908f-83c73eb1c935","StudyVersion_1"
